Sign in to download the Issue in PDF format.
1Greek Rheumatology Society and Professional Association of Rheumatologists, Private Practice, Greece
2Gastroenterology Department, Alexandra General Hospital, Athens, Greece
M Krikelis
, E Papathanasiou, G Leonidakis, P Pardalis, S Michopoulos, E Zampeli
Introduction: Aberrant activation of the IL-23/IL-17 axis leads to inflammatory phenotypes with overlapping clinical characteristics. Inhibition of IL-17 has mostly an anti-inflammatory effect, but sporadic cases of new-onset IBD have been reported. Case description: We present the case of a 65-year-old male patient with new-onset Crohn’s-like disease after treatment with secukinumab for skin psoriasis. Discontinuation of the IL-17 inhibitor and high-dose corticosteroid treatment were efficient initially, but a relapse was noted during corticosteroid tapering. Administration of certolizumab pegol did partially relieve the patient, but disease remission was only achieved with subcutaneous risankizumab therapy. Discussion: Clinical trials and real-world data indicate sporadic cases of new-onset IBD in patients receiving IL-17 inhibitors. Interestingly, our case is a “treatment-resistant” one since treatment with a biologic disease-modifying drug (bDMARD) usually leads to disease remission. As such, it is crucial to investigate the special characteristics of this clinical entity.
Cite this article as: Krikelis M, Papathanasiou E, Leonidakis G, Pardalis P, Michopoulos S, Zampeli E. New-Onset, Treatment-Resistant Inflammatory Bowel Disease after Administration of Secukinumab for Plaque Psoriasis: A Case-Report and Review of the Existing Literature. Mediterr J Rheumatol 2024;35(1):150-5.
Article Submitted: 03 Jan 2024; Revised Form: 18 Jan 2024; Article Accepted: 22 Jan 2024; Available Online: 31 Mar 2024
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2024 The Author(s).
